UCon Treatment of the Symptoms of Faecal Incontinence (FI)
Safety and Performance of UCon for the Treatment of the Symptoms of Faecal Incontinence (FI) - An Early Feasibility Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Dianna Mærsk Knudsen
- Phone Number: +4540517712
- Email: dmk@innoconmedical.dk
Study Locations
-
-
-
Barcelona, Spain, 08035
- Vall d'Hebron University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant is ≥ 18 years of age.
- Participant is showing symptoms of FI.
- Participant is able to communicate, provide feedback, understand and follow instructions during the course of the investigation, including using the device at home.
Exclusion Criteria:
- Participant is medically unstable (acute illness or complication of a chronic condition that might affect the participants´ participation in the investigation).
- Participant has an active infection in the genital area.
- Participant has an implanted pacemaker, implantable drug pump or other active medical device (any medical device that uses electrical energy or other source of power to make it function).
- Participant is pregnant, nursing or planning a pregnancy (to be confirmed with a negative pregnancy test). Women of childbearing potential must maintain effective contraception* during the interventional period judged by the investigator.
- Participant is enrolled or planning to enrol in another clinical investigation or was enrolled in an investigational drug trial or medical device investigation within four weeks to enrolment.
- Participant has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation, e.g., denervated patients and severe diabetic neuropathy.
- Participant is currently receiving cancer treatment.
- Participant has addictive behaviour defined as abuse of alcohol, cannabis, opioids, or other intoxicating drugs.
Participant does not speak and understand Spanish.
- The following contraception is considered effective: Intrauterine device, hormonal contraceptives such as birth control pills, implants, contraceptive patch, vaginal ring, and contraceptive injection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Interventional arm
Electrical stimulation to the dorsal genital nerve.
|
The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PRIMARY SAFETY: To evaluate adverse events [initial safety] of UCon for treatment of the symptoms of FI in a home setting.
Time Frame: After 28 days (4 weeks)
|
Characterization of adverse events and anticipated adverse device effects associated with the use of UCon during the investigational period.
|
After 28 days (4 weeks)
|
|
PRIMARY PERFORMANCE: To evaluate the ratio of treatment change [performance] of FI symptoms in a home setting.
Time Frame: Change from baseline at 28 days (4 weeks) and 42 days (6 weeks)
|
Ratio of subjects with at least 50% improvement of their FI symptoms from baseline.
Participants shall complete an electronic bowel diary to report their symptoms
|
Change from baseline at 28 days (4 weeks) and 42 days (6 weeks)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SECONDARY SAFETY: To identify the number of subjects experiencing adverse events associated with the use of UCon during the investigational period.
Time Frame: After 28 days (4 weeks)
|
Number of subjects experiencing adverse events and anticipated adverse device effects associated with the use of UCon.
|
After 28 days (4 weeks)
|
|
SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their quality of life.
Time Frame: Change from baseline at 28 days (4 weeks) and 56 days (8 weeks, end of study)
|
Ratio of subjects with a change in their self-reported quality of life measures as assessed by specific QoL questionnaires related to FI condition (St.
Marks incontinence score and Rockwood Fecal Incontinence Quality of Life Scale).
An overall score with greater values indicates a worse symptom outcome.
|
Change from baseline at 28 days (4 weeks) and 56 days (8 weeks, end of study)
|
|
SECONDARY PERFORMANCE: To evaluate the ratio of subject that accept UCon and DGN stimulation [Device and treatment acceptability of UCon].
Time Frame: After 28 days (4 weeks)
|
Ratio of subjects that accept UCon and DGN stimulation as assessed by a satisfaction survey recorded after each stimulation period.
|
After 28 days (4 weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Eloy Espin Basany, MD, Vall d'Hebron University Hospital, 119, 08035 Barcelona, Spanien
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ES_FEAS_01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.